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Abstract
a-Mangostin, isolated from the hulls of Garcinia mangostana L., was found to have in vitro cytotoxicity against 3T3-L1 cells
as well as inhibiting fatty acid synthase (FAS, EC 2.3.1.85). Our studies showed that the cytotoxicity of a-mangostin with IC50
value of 20 mM was incomplicated in apoptotic events including increase of cell membrane permeability, nuclear chromatin
condensation and mitochondrial membrane potential (DYm) loss. This cytotoxicity was accompanied by the reduction of
FAS activity in cells and could be rescued by 50 mM or 100 mM exogenous palmitic acids, which suggested that the
apoptosis of 3T3-L1 preadipocytes induced by a-mangostin was via inhibition of FAS. Futhermore, a-mangostin could
suppress intracellular lipid accumulation in the differentiating adipocytes and stimulated lipolysis in mature adipocytes,
which was also related to its inhibition of FAS. In addition, 3T3-L1 preadipocytes were more susceptible to the cytotoxic
effect of a-mangostin than mature adipocytes. Further studies showed that a-mangostin inhibited FAS probably by
stronger action on the ketoacyl synthase domain and weaker action on the acetyl/malonyl transferase domain. These
findings suggested that a-mangostin might be useful for preventing or treating obesity.
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Introduction
Obesity is a complex metabolic disorder, which affects normal
functions of the whole body. Since involved in various serious
diseases including type 2 diabetes, hypertension, coronary heart
disease, apoplexy, osteoarthritis and cancers, obesity has become a
worldwide public health threat [1]. Many parts of human body
can be served as targets in treating obesity, one of which is aim at
fat storage tissue by regulating fat synthesis/lipolysis/adipose
differentiation or apoptosis [2]. Fatty acid is an important source
of fat synthesis, but excess of their ectopic accumulation in other
functional organs will lead to lipotoxicity, fatty liver and insulin
resistance or other obesity-related diseases [3]. The de novo
synthesis of long chain fatty acids are catalyzed by fatty acid
synthase (FAS, EC 2.3.1.85), which has been considered as an
anti-obesity target recently. FAS not only connects with metabolic
substrates, and represents an important link in feeding regulation
[4–6]. C75, a traditional FAS inhibitor, could inhibit orexis in the
central system and stimulate carnitine palmitoyltransferase-1
(CPT-1), which promotes the oxidation of fatty acids and increases
the levels of ATP in the periphery [6,7]. Therefore, inhibiting FAS
may significantly reduce weight and treat obesity under the dual
mechanism [8].
Obesity is caused by increased adipose tissue mass, which
resulting from increased fat-cell numbers (hyperplasia) and size
(hypertrophy), accompanies by the unbalance between energy
intake and expenditure [9]. Adipose tissue consists of mature
adipocytes, pradipocytes, endothelial cells, macrophages, fibro-
blasts, and adiposederived stem cells (ADSC), among which
approximately one third is mature adipocytes and the remaining is
a combination of small blood vessels, nerve tissue, fibroblasts and
preadipocytes in various stages of development [10]. Preadipocytes
are capable to propagate and differentiate into mature adipocytes,
which determines the number of fat cells throughout their entire
lifespan [11]. Meanwhile, the size of fat-cell depends on the lipids
accumulation in the adipocytes. Therefore, adipose tissue mass can
be reduced by the inhibition of adipogenesis from preadipocytes to
mature adipocytes, prevention of lipid accumulation in adipocytes,
and induction of apoptosis in adipose cells, which can also
contribute to the treatment of obesity.
The fruit hulls of Garcinia mangostana Linn, family Guttiferae, has
been used for hundreds of years around the world, mainly in
Southeast Asia, as a traditional herbal medicine for the treatment
of abdominal pain, dysentery, wound infections, eczema, suppu-
ration, and chronic ulcer [12,13]. a-Mangostin, the dominant
xanthone found from the fruit hulls of Garcinia mangostana L., has
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33376been demonstrated by pharmacological studies to possess
antioxidant [14–16], antibacterial [12,17,18], antiinflammatory
[19], antitumor [20–29] and renoprotective [26] activities.
This study investigated for the first time the effect of a-
mangostin, isolated from the hulls of G. mangostana L., to FAS, and
the subsequent apoptotic effect on 3T3-L1 preadipocytes,
promotion of mature adipocytes lipolysis and inhibition of lipid
accumulation during the differentiation of 3T3-L1 preadipocytes
into mature adipocytes. And explore the utilite prospective of a-
mangostin as a drug candidate in treating obesity.
Results
Inhihitory effect of a-mangostin on viability of 3T3-L1
preadipocytes
To identify whether a-mangostin could inhibit the proliferation
of 3T3-L1 preadipocytes, the cells were treated with 0–36 mM a-
mangostin and proliferative capability was determined by MTT
assay. As shown in Fig. 1, a-mangostin showed strong inhibition
on cell population growth in a dose- and time-dependent manner
with 50% growth inhibitory concentration (IC50) value of 20 mM,
and it needed 13.5 h to inhibit 50% cell population growth while
in the concentration of 30 mM.
Apoptotic effect of a-mangostin on 3T3-L1
preadipocytes
In order to examine whether the inhibitory effect on 3T3-L1
preadipocytes by a-mangostin was due to it induced apoptotic cell
death, several apoptotic events including increase of cell
membrane permeability, nuclear chromatin condensation and
mitochondrial membrane potential (DYm) loss were tested. After
exposed to 0.1% DMSO (control) or a-mangostin (18 mM and
30 mM) for 24 h, apoptosis of 3T3-L1 preadipocytes was
demonstrated by Hoechst 33258 staining, revealed cell membrane
permeability increasement and nuclear condensation (Fig. 2A &
B), and by JC-1 staining, which showed the fluorescence changed
from red to green, reflected the collapse of mitochondria
membrane potential (Fig. 2C).
The effects of a-mangostin on 3T3-L1 preadipocytes is
related to its inhibition to FAS
Since a-mangostin was found to have inhibitory activity on
FAS, we extended our investigation to the intracellular FAS
activities after treated with a-mangostin. As shown in Fig. 3, 3T3-
L1 preadipocytes treated with a-mangostin at the concentration of
12 mM, 18 mM and 30 mM for 24 h, after which the reduction of
intracellular FAS activities at a level of 30%, 50% and 80%,
compared with control.
To confirm that the apoptotic effect induced by a-mangostin
was related to FAS inhibition, 3T3-L1 preadipocytes were exposed
to 0–30 mM a-mangostin for 24 h in the presence of 0, 25, 50,
100 mM palmitic acid. Results showed that 50 mM and 100 mM
exogenous palmitic acid could completely rescue the apoptosis
induced by a-mangostin (Fig. 4A). In addition, the amount of
intracellular fatty acids in 3T3-L1 preadipocytes, treated or
untreated with 30 mM a-mangostin in the presence of additional
different concentrations of palmitic acids or not, were measured.
Results (Fig. 4B) showed that the intracellular level of fatty acids in
treated 3T3-L1 preadipocytes with 30 mM a-mangostin decreased
by 43% compared with the control (4.2 mM). When 25 mM,
50 mM and 100 mM additional exogenous palmitic acids were
added into cell culture media, the amount of intracellular fatty
acids in 3T3-L1 preadipocytes raised to 3.8 mM, 5.1 mM and
5.6 mM. However, exogenous palmitic acids seem to have no effect
on a-mangostin-untreated 3T3-L1 preadipocytes, though the
amount of intracellular fatty acids increased.
These results suggest that the effect of a-mangostin on 3T3-L1
preadipocytes is well correlated with its inhibitory activity on FAS.
Effects of a-mangostin on the lipogenesis and lipolysis of
3T3-L1 preadipocytes
To examine whether a-mangostin could suppress the differen-
tiation of 3T3-L1 preadipocytes at a low dosage without
cytotoxicity, the cells were exposed continuously to 6 and 12 mM
a-mangostin during the differentiation period for 8 days, and then
the intracellular lipid accumulation was determined. As shown in
Fig. 5, 6 and 12 mM a-mangostin failed to affect the cell viability,
Figure 1. Effect of a-mangostin on proliferation of 3T3-L1 preadipocytes. (A) Cells were incubated with 0–36 mM a-mangostin for 24 h at
37uC in humidified 5% CO2 incubator. (B) Cells were incubated with 0, 6, 12, 24, 30 mM a-mangostin for 6–24 h at 37uC in humidified 5% CO2
incubator. Assays were performed on eight replicates for each treatment. Results are expressed as percentages of cell viability as compared with
untreated control (means 6 S.D., n=8). The experiments were repeated in twice.
doi:10.1371/journal.pone.0033376.g001
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with control, respectively. For mature 3T3-L1 adipocytes, cell sizes
were shrunk when treated with 18 and 30 mM a-mangostin
(Fig. 6B). In addition, 30 mM a-mangostin promoted 15% lipid to
lipolysis, compared to control (Fig. 6D). Simultaneously, 74% FAS
activity was inhibited (Fig. 6C).
Effect of a-mangostin on viability of 3T3-L1
preadipocytes in different differentiationstages
To examine further effect of a-mangostin on different stages of
adipocyte differentiation, 3T3-L1 cells were exposed to a series
concentrations of a-mangostin for 24 h at given time points (d2,d 4
or d8), then the cell viability were measured (Fig. 7). Interestingly,
as 3T3-L1 preadipocytes differentiated, they appeared to gain the
ability to resist the suppression from a-mangostin. As shown in
Fig. 1, 50% 3T3-L1 preadipocytes lost their cell viability when
treated with 20 mM a-mangostin. However, after cells were
induced for 4 days, only 10% cells lost their viability when treated
with 36 mM a-mangostin. After 3T3-L1 cells developed into
mature adipocytes, 36 mM a-mangostin had no cytotoxic effect on
cells. These results indicated that 3T3-L1 preadipocytes were
more susceptible to the cytotoxic effect of a-mangostin than
mature adipocytes.
Kinetic mechanism of inhibition of FAS by a-mangostin
In order to explore the inhibition mechanism on FAS of a-
mangostin, the inhibitory kinetics was studied. Lineweaver-Burk
analysis of the kinetic data showed that a-mangostin inhibited the
overall reaction of FAS in a competitive manner with respect to
acetyl-CoA (Fig. 8A) and a noncompetitive manner with respect to
malonyl-CoA (Fig. 8B). a-Mangostin had no slow-binding
irreversible inhibition effect on FAS (Fig. 8C).
These results suggest that a-mangostin might act reversibly on
the acetyl binding group of FAS but not malonyl group. So the
acting sites of a-mangostin on FAS were most likely on acetyl/
malonyl transferase domain (MAT), or b-ketoacyl synthase
domain (KS) or both. The activities of individual reactions in
FAS overall reactions were measured in the presence of a-
mangostin (Fig. 8D). It is found that b-ketoacyl and enoyl
reduction reactions were slightly influenced by a-mangostin, which
indicates that a-mangostin does not act on the b-ketoacyl
reductase (KR) and enoyl reductase (ER) domains of FAS. The
results are consistent with former hypothesis. In order to define the
actual acting sites of a-mangostin on FAS, we assayed the effect of
a-mangostin against acetoacetyl-CoA reduction which entails
catalytic reaction by MAT. As shown in Fig. 1D, a-mangostin
has the ability to inhibit acetoacetyl-CoA reduction of FAS, with
IC50 value of 28 mM, which is about 5-fold weaker than that of
FAS overall reaction (IC50=5.54 mM). This comparison shows
that a-mangostin strongly acts on the domain of FAS which is not
included in the domains required in the acetoacetyl-CoA
reduction. So we conclude that a-mangostin inhibits FAS on the
acetyl binding sites of KS more stronger than that of MAT.
Discussion
Inhibition of FAS in animal reduced food intake and body
weight, which suggested that inhibiting intracellular FAS should
be a reasonable way for treating obesity and related diseases. As a
novel FAS inhibitor, a-mangostin may be applied practically in
treating obesity or health care. The present study showed that a-
mangostin can reduce adipose tissue mass by reducing fat-cell
numbers and shrinking their sizes (See Fig. 5 and Fig. 6A, 6B).
Firstly, when 3T3-L1 preadipocytes were treated with a-
mangostin, their viabilities appeared to be reduced in a dose-
and time-dependent manner, with the IC50 value of 20 mM. About
90% of 3T3-L1 preadipocytes lost their viabilities by treating with
36 mM a-mangostin in 24 h. However, 6–12 mM a-mangostin had
slightly cytotoxicity to preadipocytes (Fig. 1). Higher concentration
of a-mangostin could induce cell apoptosis of 3T3-L1 preadipo-
cytes which was evidenced by increased cell membrane perme-
ability, nuclear chromatin condensation and mitochondrial
membrane potential (DYm) loss (Fig. 2). Induction of apoptosis
in cells can lead to their own destruction into apoptotic bodies
which can be cleared by surrounding phagocytic cells without
inducing a local damaging inflammatory response [30,31], so
apoptosis is thought to be a normal and efficient way by which
human body weeds out dead and waste cells. Like other cells,
adipose cell has its own lifespan, during which preadipocytes
propagate and differentiate into mature adipocytes to renew,
replenish and keep the numbers of fat cells. Since a-mangostin can
Figure 2. a-mangostin-induced 3T3-L1 preadipocytes apopo-
tosis. 3T3-L1 preadipocytes were treated with a-mangostin at the
indicated concentrations for 24 h. (A) Effect of a-mangostin on cell
membrane permeability: original magnification, 640; exposure times:
20s; (B) Effect of a-mangostin on nuclear chromatin morphology with
Hoechst 33258 staining: original magnification, 6200; exposure times:
100s. (C) Effect of a-mangostin on mitochondria membrane potential
(DYm) with JC-1 staining: original magnification, 640; exposure times:
100 s. B. field, bright field; H.33258, Hoechst 33258; JC-1, 5,5,6,6-
tetrachloro-1,1,3,3-tetraethylbenzimidazolcarbocyanine iodide. The ex-
periments were performed on four replicates for each treatment.
Representative images are shown.
doi:10.1371/journal.pone.0033376.g002
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reduction of adipose cells, adipose tissue treated with a-mangostin
avoids hyperplasia.
Secondly, lower concentration of a-mangostin (6 mM and
12 mM) inhibits lipid accumulation during adipose differentiation
period. As shown in Fig. 5, although 6 mM and 12 mM a-
mangostin failed to induce cell apoptosis, they reduce the lipid
accumulation by 20% and 60% of control, respectively. It
indicated that the reduction of lipid resulted from inhibition of
lipid accumulation, but not from reducing number of preadipo-
cytes. Also, a-mangostin in higher concentration promotes lipid to
lipolysis but not decrease cell numbers for the muture adipocytes
Figure 3. Effect of a-mangostin on FAS activity in 3T3-L1 preadipocytes. 3T3-L1 preadipocytes were treated with a-mangostin at the
indicated concentrations for 24 h. FAS specific activity was determined by Cell FAS activity assay. Data are expressed as means 6 S.D. (n=3). * p,0.05
different from control (0 mM); ** p,0.01significantly different from control (0 mM).
doi:10.1371/journal.pone.0033376.g003
Figure 4. The effect of exogenous palmitic acid on 3T3-L1 preadipocytes. (A) 3T3-L1 preadipocytes were treated with a-mangostin and
palmitic acid at various concentrations (a-mangostin: 0, 6, 12, 18, 30 mM; palmitic acid: 0, 25, 50, 100 mM) for 24 h. Cell viability was determined by
MTT colorimetric assay. Assays were performed on eight replicates for each treatment. Results are expressed as percentages of cell viability as
compared with untreated control (means 6 S.D., n=8). The experiment was repeated in twice. (B) The 3T3-L1 preadipocytes were treated with a-
mangostin and palmitic acid at various concentrations (a-mangostin: 0, 30 mM; palmitic acid: 0, 25, 50, 100 mM) for 24 h. And then the amount of
intracellular fatty acid was determined by Fatty Acid Assay Kit. Data are expressed as means 6 S.D. (n=3). * p,0.05 different from respective control;
** p,0.01 significantly different from respective control.
doi:10.1371/journal.pone.0033376.g004
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mangostin. Therefore, inhibition of adipogenesis and stimulation
of lipolysis by a-mangostin may be a beneficial method to control
hypertrophy in adipose tissue. Recent studies have shown that
many FAS inhibitors could suppress lipid accumulation during
adipocyte differentiation [32–35]. The effect of a-mangostin on
3T3-L1 preadipocytes and muture adipocytes, as shown in Fig. 3
and Fig. 6C, is also according to the inhibition of FAS activity. It
shows that a-mangostin can decrease the amount of intracellular
fatty acids in 3T3-L1 preadipocytes, but additional exogenous
palmitic acids can raise the amount of intracellular fatty acids
(Fig. 4B). And the cytotoxicity of a-mangostin on 3T3-L1
preadipocytes can also be rescued by 50 mM and 100 mM
exogenous palmitic acid (Fig. 4A). It is indicated that the apoptotic
effect of a-mangostin on 3T3-L1 cells is related to its inhibition on
FAS. Inhibition of FAS has been reported to promote apoptosis by
activating the cellular intrinsic pathway of apoptosis, which was
demonstrated by annexin V-positive cells, the cytochrome c
release and caspase-9 and -3 activation [36]. In addition,
inhibition of FAS results in the accumulation of malonyl-CoA,
which leads to inhibition of CPT-1 and up-regulation of ceramide
and induction of the proapoptotic genes BNIP3, TRAIL, and
DAPK2, resulting in apoptosis [37].
In our previous study, a-mangostin was found to inhibit FAS
overall reaction with IC50 value of 5.54 mM [38]. In this study, we
assayed its inhibition kinetics to explore its specific acting sites on
FAS. After pertinent experiment, we found that the b-ketoacyl and
enoyl reductions of FAS were slightly influenced by a-mangostin,
which indicates that the two reductases domains are not the acting
site of a-mangostin (Fig. 8D). The inhibition kinetic results in vitro
showed that a-mangostin inhibited FAS against substrate acetyl
CoA competitively, and against another substrate malonyl CoA
noncompetitively (Fig. 8A–B), which suggested that a-mangostin
may bind to acetyl but not malonyl group on FAS. In FAS, KS
could bind to acetyl but not malonyl group [39,40], and MAT has
different active binding sites for acetyl and malonyl [41].
Therefore, KS and MAT are likely to be the sites a-mangostin
may act on. To figure out clearly which sites a-mangostin may act
on, acetoacetyl CoA reduction activity, which includes catalytic
reaction by MAT but not KS, was assayed. a-Mangostin inhibited
this reaction with IC50 value of 28 mM (Fig. 8D) that is about 5-
fold of that of the inhibition for FAS overall reaction. These results
suggested that a-mangostin inhibit FAS probably by stronger
action on the KS domain and weaker action on the MAT domain.
In conclusion, our study indicates that a-mangostin inhibits
intracellular FAS by mainly acting on the KS domain of FAS.
Moreover, a-mangostin is effective in inducing apoptosis of
preadipocyte, suppressing adipocyte differentiation, reducing lipid
accumulation and causing lipolysis of mature adipocyte, which is
due to the inhibition of FAS. The mechanism of this result is
unclear. It has been shown that the specific activity of FAS in
mature adipose cells is greatly higher than in preadipocytes (Fig. 3
& Fig. 6). Although 30 mM a-mangostin could suppress 74% FAS
activity (Fig. 6), it is not enough to reach the degree to induce cell
apoptosis. So it is likely to need higher concentration of a-
mangostin to reach the same suppressive effect with it testing on
undifferentiated cells. Another explanation is that during adipo-
cyte differentiation, some resistance factors are expressed by
Figure 5. Inhibitory effect of a-mangostin on intracellular lipid accumulation. The intracellular lipid content was measured by Oil Red O
staining as described in Materials and Methods. (A) Cells were photographed at 406 magnification. The experiment was performed on three
replicates for each treatment. Representative images are shown. (B) Quantitative analysis of lipid accumulation. Each value is expressed as means 6
SD (n=3). * p,0.05 different from control (0 mM); ** p,0.01 significantly different from control (0 mM).
doi:10.1371/journal.pone.0033376.g005
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was reported to augment, which is closely correlated with the
development of resistance to apoptosis induced by growth factor
deprivation [42]. NAIP is one of the inhibitors of apoptosis (IAPs)
family, which suppress apoptosis [43]. Besides, it is found that
there was a significant increase during adipocyte differentiation in
the expression of Bcl-2 protein which retains cytochrome c within
the mitochondria, suggesting a possible role for this pro-survival
factor in the acquisition of apoptotic resistance in adipose cells
[44]. Perhaps these factors also play the role in mature adipocyte
cells resistance to apoptosis induced by a-mangostin.
Considering multitargeted therapy is possibly better than mono-
targeted therapy for obesity, our results suggest that a-mangostin
could be considered to have the application potential in preventing
ortreating obesity, and itmay supply someuseful idea and new clues
in developing drugs in treatment of obesity.
Materials and Methods
Materials
Acetyl-CoA, Malonyl-CoA, Insulin (INS), Dexamethasone
(DEX), Oil red O, NADPH, MTT dye, Hoechst-33258, 3-
isobutyl-1-methylxanthine (IBMX), Palmitic acid, EDTA and
DTT were purchased from Sigma. Dulbecco’s modified Eagle’s
medium (DMEM) and fetal bovine serum were purchased from
GIBCO BRL. a-Mangostin ($98%) was isolated and purified
Figure 6. Effect of a-mangostin on lipolysis and FAS activity in 3T3-L1 mature adipocytes. 3T3-L1 mature adipocytes were treated for at
the indicated concentrations for 24 h, and then the intracellular lipid content, cell FAS activity were measured and cell sizes were compared. (A) Cells
were photographed at 406magnification. The experiment was performed on three replicates for each treatment. Representative images are shown.
(B) Cells were photographed at 2006magnification. The experiment was performed on three replicates for each treatment. (C) Reduction of FAS
activity. Data are expressed as means 6 S.D. (n=3).(D) Quantitative analysis of lipid lipolysis. Each value is expressed as means 6 SD (n=3). * p,0.05
different from control (0 mM); ** p,0.01 significantly different from control (0 mM).
doi:10.1371/journal.pone.0033376.g006
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other reagents were local products with analytical grade.
Cell culture
Culture of 3T3-L1 preadipocytes. Mouse 3T3-L1
preadopocytes were obtained from the Cell Culture Center of
the Institute of Basic Medical Sciences (IBMS), Chinese Academy
of Medical Sciences (Beijing, China). 3T3-L1 preadipocytes were
incubated in DMEM, 10% fetal bovine calf serum, 100 U/ml
penicillin-streptomycin.
Differentiation of 3T3-L1 preadipocytes. Two days after
confluence (Day 0, d0), the cell differentiation was induced in
DMEM containing 10% FBS, 0.5 mM IBMX, 1 mMD E X ,a n d
1.7 mM INS for two days (Day 2, d2, early stage), and another two
days (Day 4, d4, middle stages) in DMEM containing 10% FBS and
1.7 mM INS. Cells weremaintained inDMEMcontaining 10% FBS
everyotherdayforthe following fourdays (Day6–8,d6–8,la test ag e) .
All experiments were strictly carried out on cell lines between 5–
20 passages. All cell culture condition was 37uC in a humidified
5% CO2 incubator. The a-mangostin was conserved in DMSO
before added into the culture medium.
MTT assay
3T3-L1 preadipocytes were seeded in 96-well plate (5610
3
cells/well) and then treated with a-mangostin in different
concentrations for the next 6–24 hrs. Thereafter, 20 ml of MTT
solution (5 mg MTT/mL in PBS) was added into each well of a
microtiter plate and incubated for 4 h at 37uC. The resultant
formazan product was dissolved in 200 ml DMSO/well, and its
concentration was measured at 492 nm by a microplate
spectrophotometer (Multiskan, MK3).
To verify the effects of a-mangostin on 3T3-L1 cells
preadipocytes at different adipogenic stage (early, middle and late
stage), the cell viability was measured by the MTT assay. Briefly,
2610
5 cells/well were seeded in 24-well plate and a-mangostin in
different concentrations was added into the wells at d2,d 4,d 8 and
then incubated at 37uC for 24 h. The MTT assay was performed
according to the above instructions.
Intracellular fatty acids assay
The amount of intracellular fatty acid was determined by Fatty
Acid Assay Kit. Briefly, 3T3-L1 preadipocytes were seeded in
100 mm cell culture dishes. After experimental treatment, cells
were washed twice with PBS, and then extracted by homogeni-
zation with 200 ml of chloroform-Triton X-100 (1% Triton X-100
in pure chloroform) in a microhomogenizer. Then spin the extract
5–10 min at top speed in a microcentrifuge. Collect organic phase
(lower phase), air dry at 50uC to remove chloroform. Vacuum dry
30 min to remove trace chloroform. Dissolve the dried lipids in
200 ml of Fatty Acid Assay Buffer by vortexing extensively for
5 min. Add 2 ml ACS Reagent into all sample wells and incubate
the reaction at 37uC for 30 min. Add 50 ml of the Reaction Mix
containing 44 ml Assay Buffer, 2 ml Fatty Acid Probe, 2 ml Enzyme
Mix and 2 ml Enhancer to the test samples. Incubate the reaction
for 30 min at 37uC, protected from light. The colorimetric assay
was measured at 570 nm by a microplate spectrophotometer.
Hoechst 33258 Staining
3T3-L1 preadipocytes were seeded in 12-well culture dishes
(5610
4 cells/well). After experimental treatment, cells were
washed twice with PBS, and stained with Hoechst-33258 (5 mg/
ml) for 5 min in the dark, and then followed by extensive washes.
Nuclear staining was examined under the fluorescence microscope
and images were captured using ImagePro Plus software
(MediaCybernetics, Silver spring, MD).
Figure 7. Effect of a-mangostin on cell viability of 3T3-L1 cells in different stages of adipocyte differentiation. 3T3-L1 cells were
exposed to various concentrations of a-mangostin at various time points (d2,d 4 or d8) for 24 h, then the cell viability were measured by MTT assay.
Assays were performed on four replicates for each treatment. Results are expressed as percentages of cell viability as compared with each untreated
control (means 6 S.D., n=4). The experiment was repeated in triplicate. Early stage: d0-d2; Middle stage: d2-d4; Late stage: d4-d8.
doi:10.1371/journal.pone.0033376.g007
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Mitochondria membrane potential was determined by using the
mitochondrial membrane potential assay kit with JC-1 (Beyotime
Biotech, Nantong, China). Briefly, 3T3-L1 preadipocytes were
seeded in 12-well plates. After experimental treatment, cells were
washed twice with PBS, and then added 1 ml staining dye/well
(culture medium: JC-1 working dye =1:1) and incubated at 37uC
for 20 min. After this, cells were washed twice with cold JC-1
staining buffer (16), and examined under the fluorescence
microscope and images were captured using ImagePro Plus
software (MediaCybernetics, Silver spring, MD).
Oil Red O staining
To investigate the effects of a-mangostin on lipid accumulation in
3T3-L1preadipocytes,the cellsweredifferentiatedinthepresenceof
a-mangostin at various concentrations. Intracellular lipid accumu-
lation was determined by Oil Red O staining at day 8. Cells were
washed twice with PBS and stained with Oil Red O (six parts 0.6%
Oil Red O dye in isopropanol and four parts water) for 1 h. After
washed three times with distilled water, cells were photographed
under the microscope. Lipid and Oil red O were dissolved in
isopropanol and absorbance was measured by the microplate
spectrophotometer (Multiskan, MK3) at the wavelength of 492 nm.
Cell FAS activity assay
FAS activity in cells was assessed as described previously with
appropriate modifications [21]. After cells were harvested, pelleted
by centrifugation, resuspended in cold assay buffer (100 mM
potassium phosphate buffer, 1 mM EDTA, 0.6 mM PMSF and
1 mM dithiolthreitol, pH 7.0), ultrasonically disrupted and
centrifuged at 12000 rpm for 30 min at 4uC, the supernatant
was collected for the overall reaction assay. 25 ml supernatant was
added into the reaction mix contained 25 mM KH2PO4-K2HPO4
buffer, 0.25 mM EDTA, 0.25 mM dithiothreitol, 30 mM acetyl-
CoA, 100 mM malonyl-CoA, 350 mM NADPH (pH 7.0) in a total
volume of 200 ml. Protein content in the supernatant was
Figure 8. Inhibitory effects of a-mangostin on FAS activities. (A) and (B) Lineweaver-Burk plots for inhibition of FAS overall reaction: (A)
Acetyl-CoA was the variable substrate. The concentrations of a-mangostin were 0 mM( X); 5 mM(N); 10 mM( m); 15 mM( +). (B) Malonyl-CoA was the
variable substrate. The concentrations of a-mangostin were 0 mM( X); 5 mM(N); 10 mM( m); 15 mM( +). (C) Time courses of the overall reaction in the
presence of a-mangostin. The reaction was determined by slow-binding inhibition assay. (D) Inhibition of FAS overall reaction and some partial
reactions of FAS.
doi:10.1371/journal.pone.0033376.g008
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results are expressed as the specific activity of FAS (U/mg).
FAS activity assay
Preparation of FAS and its substrate. The preparation,
storage and use of fatty acid synthase from chicken liver were
performed as described previously [45]. The amino acid sequence of
human FAShas63%identitywiththesequencesofchickenenzymes
[46]. The purified FAS was homogeneous on polyacrylamide gel
electrophoresis in the presence and absence of sodium dodecyl
sulfate (SDS). The concentrations of the enzyme and substrate were
determined by Amersham Pharmacia Ultrospec 4300 pro UV-Vis
spectrophotometer (England, UK) spectrophotometer using the
following extinction coefficients: FAS, 4.83610
5 M
21 cm
21 at
279 nm; acetyl-CoA, 1.54610
4 M
21 cm
21at 259 nm, pH 7.0;
malonyl-CoA,1.46610
4 M
21 cm
21at 260 nm, pH 6.0; NADPH,
6.02610
3 M
21 cm
21 at 340 nm, and 1.59610
4 M
21 cm
21at
259 nm, pH 9.0 [47].
Assays of FAS activity. The FAS activity was measured by
following the decrease of NADPH absorption at 340 nm using an
Amersham Pharmacia Ultrospec 4300 pro UV-Vis spectro-
photometer at the constant temperature of 37uC. The overall
reaction system contained 100 mM KH2PO4-K2HPO4 buffer,
1 mM EDTA, 1 mM dithiothreitol, 3 mM acetyl-CoA, 10 mM
malonyl-CoA, 35 mM NADPH, and 10 mg FAS in a total volume
of 2 ml as previously described [45,47,48]. The acetoacetyl-CoA
reduction reaction mixture contained 100 mM KH2PO4-
K2HPO4 buffer, pH 7.6, 25 mM acetoacetyl-CoA, 35 mM
NADPH, 1 mM EDTA and 40 mg FAS in a total volume of
2 ml. Acetoacetyl-CoA reduction reaction includes transacylation,
b-ketoacyl reduction, dehydration and enoyl reduction, which are
catalyzed by four component enzymes and ACP in fatty acid
synthase [49]. After temperature equilibration at 37uC for 10 min,
the reaction was initiated by the addition of FAS and the initial
velocity was determined from the decrease in absorbance at
340 nm. b-ketoacyl reduction reaction mixture contained
100 mM KH2PO4-K2HPO4 buffer, pH 7.0, 200 mM ethyl
acetoacetate, 35 mM NADPH, 1 mM EDTA and 20 mg FAS in
a total volume of 2 ml [50]. The enoyl reduction reaction mixture
contained 100 mM KH2PO4-K2HPO4 buffer, pH 6.3, 40 mM
ethyl crotonate, 35 mM NADPH, 1 mM EDTA and 80 mg FAS in
a total volume of 2 ml.
Assays of FAS inhibition. Fast-binding inhibition was
determined by adding a-mangostin to the reaction system before
FAS initiated the reaction. The activities of FAS with and without
a-mangostin were represented as Ai and A0. The value of Ai/
A06100% was the remaining activity (R.A.) of FAS. The value of
50% inhibition concentration (IC50) was calculated from the plot
of remaining activity versus a-mangostin concentration with
Origin 8.0 program. Dissolution of a-mangostin was lower in
0.5% (V/V) dimethyl sulfoxide (DMSO), while FAS activity was
not affected by this concentration of DMSO (data not shown).
For the slow-binding inhibition assay, FAS solutions was
incubated with a-mangostin at room temperature for 0–
300 min, and aliquots were taken to measure the remaining
activity of FAS at different time intervals to obtain the time-course
curves. The control is treated with the same procedure without a-
mangostin.
Statistical analysis
Obtained results were analyzed by one way ANOVA test
(Origin 8.0). p values,0.05 were considered statistically significant
and p values,0.01 were considered highly significant.
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